



Docket No. VPI/96-16 CIP *GP 16* *RECEIVED* *#4* *C. Style* *APR 07 2000*

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Deepak Rao  
Group : 1611  
Applicants : Guy W. Bemis et al.  
Serial No. : 09/336,266  
Filed : June 18, 1999  
Title : INHIBITORS OF P38

New York, New York  
March 27, 2000

Hon. Assistant Commissioner  
for Patents  
Washington, D.C. 20231

TRANSMITTAL LETTER FOR  
INFORMATION DISCLOSURE STATEMENT

Sir:

Transmitted herewith is an Information  
Disclosure Statement in the above-identified application.  
This Statement is submitted:

☐ within three months of the application filing  
date;

☒ more than three months from the  
application filing date but before the  
mailing date of the first Office Action on  
the merits.

☐ after the mailing date of a first Office  
Action on the merits but before the mailing

RECEIVED

APR 07 2000

TECH CENTER 1600/2900

date of a Final Action or a Notice of Allowance.

If, for any reason, a fee is due, the Commissioner is hereby authorized to charge payment of the additional fee required to Deposit Account No. 06-1075. A duplicate copy of this letter is transmitted herewith.

Respectfully submitted,



James F. Haley, Jr. (Reg. No. 27,794)  
Attorney for Applicants  
Nandakumar Govindaswamy  
(Limited Recognition)  
Agent for Applicants  
c/o FISH & NEAVE  
1251 Avenue of the Americas  
New York, New York 10020-1104  
Tel.: (212) 596-9000

I Heroby Certify that this  
Correspondence is being  
Deposited with the U.S.  
Postal Service as First  
Class Mail in an Envelope  
Addressed to: ASSISTANT  
COMMISSIONER FOR  
PATENTS  
WASHINGTON, D.C. 20231 on

  
Claire J. Saintil

  
Signature of Person Signing



VPI96-16 CIP 2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Deepak Rao  
Group : 1611  
Applicants : Guy W. Bemis et al.  
Serial No. : 09/336,266  
Filed : June 18, 1999  
For : INHIBITORS OF P38

New York, New York  
March 27, 2000

Hon. Assistant Commissioner  
for Patents  
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§ 1.56 AND 1.97

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, applicants, through their attorney, make of record the documents listed below.\* A completed Form PTO-1449 listing all of the following documents is enclosed herewith in duplicate.

United States Patents

<u>Inventor</u>	<u>Serial No.</u>	<u>Issue Date</u>
Harold G. Selnick et al.	5,717,100	2/10/98
Jerry L. Adams, et al.	5,716,955	2/10/98
Jerry L. Adams, et al.	5,716,972	2/10/98

---

\* Applicants have previously submitted copies of these documents on December 12, 1998, along with the Information Disclosure Statement filed in the parent United States application 08/862,925, filed June 10, 1997.

### Foreign Patent Applications

<u>Applicant</u>	<u>Publication No.</u>	<u>Publication Date</u>
Smithkline Beecham Corp.	WO 98/06715	2/19/98
Pfizer Pharmaceuticals Inc.	WO 98/02430	1/22/98
Pharmacia & Upjohn S.P.A.	WO 97/49689	12/31/97
Merck & Co., Inc.	WO 97/47618	12/18/97
Signal Pharmaceuticals, Inc.	WO 97/44467	11/27/97
Merck & Co., Inc.	WO 97/12876	4/10/97
Celltech Therapeutics, Ltd.	WO 97/19065	5/29/97
Smithkline Beecham Corp.	WO 95/31451	11/23/95
Smithkline Beecham Corp.	WO 95/02591	1/26/95

### Articles

Timothy F. Gallagher, et al., "Regulation of Stress-Induced Cytokine Production by Pyridinylimidazoles; Inhibition of CSBP Kinase," Bioorganic & Medicinal Chemistry, 5(1), pp. 49-64, (1997).

Alison M. Badger, et al., "Pharmacological Profile of SB 203580, a Selective Inhibitor of Cytokine Suppressive Binding Protein/p38 Kinase, in Animal Models of Arthritis, Bone Resorption, Endotoxin Shock and Immune Function," Journal of Pharmacology and Experimental Therapeutics, 279(3), pp. 1453-1461, (1996).

Timothy F. Gallagher, et al., "2,4,5- Triaryl-imidazole Inhibitors of IL-1 Biosynthesis," Bioorganic & Medicinal Chemistry Letters, 5 (11), pp. 1171-1176, (1995).

This Statement is being submitted after the mailing date of the first substantive Action on the merits but before the mailing of a final Action or a Notice of Allowance. In

accordance with 37 C.F.R. §§ 1.97(c) and 1.17(p), applicants have enclosed herewith the requisite fee. If any additional fees are due, the Commissioner is hereby authorized to charge payment of the fee required in connection with this Information Disclosure Statement to Deposit Account No. 06-1075.


Applicants request that these documents: (1) be fully considered by the Examiner during examination of this application, and (2) be printed on any patent that may issue from this application. Applicants request that the Examiner initial and return the duplicate copy of the PTO-1449 form with the next communication.


Respectfully submitted,



James E. Haley, Jr. (Reg. No. 27,794)  
Attorney for Applicants  
Nandakumar Govindaswamy  
(Limited Recognition)  
Agent for Applicants  
c/o FISH & NEAVE  
1251 Avenue of the Americas  
New York, New York 10020  
Tel.: (212) 596-9000

I Hereby Certify that this  
Correspondence is being  
Deposited with the U.S.  
Postal Service as First  
Class Mail in an Envelope  
Addressed to: ASSISTANT  
COMMISSIONER FOR  
PATENTS  
WASHINGTON, D.C. 20231 on

  
March 23, 2000  
Claire J. Saintil

  
Signature of Person Signing